Microgynon 30

How to order Microgynon 30

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Microgynon 30 on Prescriptsy

Microgynon 30 is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Microgynon 30 is a combined oral contraceptive pill (COC) used to prevent pregnancy.

Each tablet contains two active ingredients: levonorgestrel 150 micrograms (a progestogen) and ethinylestradiol 30 micrograms (a synthetic oestrogen).

Microgynon 30 is one of the most commonly prescribed combined oral contraceptives in the United Kingdom.

It is recommended by the Faculty of Sexual and Reproductive Healthcare (FSRH) and NICE as a first-line combined oral contraceptive because it contains levonorgestrel, which is associated with the lowest risk of venous thromboembolism (VTE) among all COC formulations.

Microgynon 30 is a prescription-only medicine (POM) and is available free of charge through the NHS, GP surgeries, and sexual health clinics.

Reliable contraception is a fundamental aspect of reproductive healthcare.

Around 3.1 million women in the United Kingdom currently use some form of hormonal contraception, with the combined pill remaining one of the most popular methods.

Choosing the right contraceptive involves weighing effectiveness, convenience, potential side effects, and individual health factors.

This page provides a comprehensive clinical overview of Microgynon 30, covering how it works, dosage guidance, side effects, important safety warnings, and how to obtain a prescription in the United Kingdom.

Important safety information about Microgynon 30

• Microgynon 30 is a prescription-only medicine that should be used under medical supervision.
• All combined oral contraceptives carry a small increased risk of blood clots (VTE). Microgynon 30 carries the lowest VTE risk among combined pills.
• Do not take Microgynon 30 if you experience migraine with aura, as this significantly increases the risk of stroke.
• Smoking while taking the combined pill increases cardiovascular risk. Women over 35 who smoke must not use combined oral contraceptives.
• Microgynon 30 does not protect against sexually transmitted infections. Use condoms for STI protection.

Understanding combined oral contraception

Combined oral contraceptives contain two types of hormone: an oestrogen and a progestogen. The oestrogen component in Microgynon 30 is ethinylestradiol, a synthetic oestrogen used in most COCs.

The progestogen component is levonorgestrel, a second-generation progestogen that has been used in oral contraceptives since the 1960s and has the longest safety record of any progestogen in current clinical use.

Microgynon 30 is a monophasic pill, meaning every active tablet delivers the same dose of both hormones, which simplifies use and allows flexibility in adjusting the regimen.

The generation of progestogen is clinically relevant because it influences the VTE risk profile. First-generation progestogens (norethisterone) are rarely used in modern COCs.

Second-generation progestogens (levonorgestrel, norgestrel) are associated with the lowest VTE risk among COCs.

Third-generation progestogens (desogestrel, gestodene) carry a slightly higher VTE risk but may have fewer androgenic side effects.

The FSRH and NICE recommend COCs containing levonorgestrel with 30 micrograms ethinylestradiol as first-line options because they offer the most favourable balance of efficacy and VTE risk.

How Microgynon 30 works: mechanism of action

Microgynon 30 prevents pregnancy through three complementary mechanisms. The primary mechanism is the suppression of ovulation.

Ethinylestradiol and levonorgestrel together inhibit the release of gonadotrophins (follicle-stimulating hormone and luteinising hormone) from the anterior pituitary gland, preventing the mid-cycle LH surge that triggers ovulation.

Without ovulation, no egg is released for fertilisation.

The second mechanism involves changes to the cervical mucus.

Levonorgestrel causes the cervical mucus to become thicker and more viscous, creating a physical barrier that impedes sperm transport through the cervix into the uterus.

This effect is maintained throughout the pill-taking cycle and provides additional contraceptive protection even if ovulation suppression is not complete.

The third mechanism is the alteration of the endometrium (womb lining). The hormonal environment created by Microgynon 30 makes the endometrium less receptive to implantation.

While this is considered a secondary contributor to contraceptive efficacy, it provides an additional layer of protection.

Clinical evidence and UK prescribing guidance

Combined oral contraceptives are among the most thoroughly studied medicines in clinical use, with over 60 years of evidence.

The efficacy of levonorgestrel/ethinylestradiol COCs in preventing pregnancy is well established, with a Pearl Index of approximately 0.1 to 0.5 with perfect use and around 9 with typical use.

The FSRH guideline on combined hormonal contraception (updated 2019) recommends COCs containing levonorgestrel or norethisterone with 30 micrograms ethinylestradiol as the first choice when a combined pill is appropriate, because they carry the lowest VTE risk.

NICE guidance on contraception recommends offering women a choice of methods with counselling about comparative risks and benefits.

The decision to prescribe a particular COC should be shared between the prescriber and the woman.

An important clinical consideration is the UK Medical Eligibility Criteria (UKMEC) for contraceptive use, published by the FSRH.

This document categorises medical conditions according to their suitability for each contraceptive method. Category 1 means no restriction on use.

Category 2 means the advantages generally outweigh the risks. Category 3 means the risks generally outweigh the advantages. Category 4 means an unacceptable health risk.

Microgynon 30, like all COCs, is Category 4 for women with migraine with aura, current or past VTE, or certain cardiovascular conditions.

Microgynon 30 compared with other combined pills

The UK market offers a wide range of combined oral contraceptives.

Rigevidon contains the same active ingredients as Microgynon 30 (levonorgestrel 150 micrograms and ethinylestradiol 30 micrograms) and is a generic equivalent.

Marvelon and Mercilon contain desogestrel (a third-generation progestogen); Marvelon has 30 micrograms ethinylestradiol and Mercilon has 20 micrograms.

Third-generation pills may have fewer androgenic side effects but carry a slightly higher VTE risk (9 to 12 per 10,000 users per year versus 5 to 7 for levonorgestrel-containing pills).

Yasmin contains drospirenone with 30 micrograms ethinylestradiol and may be preferred for women with acne or fluid retention, though its VTE risk is similar to third-generation pills.

Loestrin 20 and similar low-dose pills contain 20 micrograms ethinylestradiol with norethisterone.

Lower oestrogen doses may reduce oestrogen-related side effects (headaches, breast tenderness, nausea) but may increase breakthrough bleeding.

Eloine and Qlaira use estradiol valerate (natural oestrogen) instead of ethinylestradiol and represent newer developments in COC formulation.

The progestogen-only pill (POP), such as Cerazette (desogestrel 75 micrograms) or Hana (available over the counter), is an alternative for women who cannot or prefer not to take oestrogen.

Long-acting reversible contraceptives (LARCs), including the intrauterine system (Mirena), the subdermal implant (Nexplanon), and the injectable (Depo-Provera), offer higher effectiveness with less reliance on daily adherence and are recommended by NICE as first-line options where appropriate.

Dosage and administration

Take one Microgynon 30 tablet at the same time each day for 21 days. Swallow the tablet whole with water.

Each blister strip is marked with the days of the week to help with tracking. After completing 21 tablets, stop for 7 days.

A withdrawal bleed will usually occur during this break. Start the next strip on day 8, whether or not bleeding has finished.

Setting a daily alarm or linking pill-taking to a routine activity helps maintain consistency.

If you start on day 1 of your period, protection is immediate. Starting at any other time requires 7 days of additional barrier contraception.

Missed pill rules follow FSRH guidance: one missed pill requires no extra precautions; two or more require condoms for 7 days and, if fewer than 7 pills remain, omit the break.

Extended regimens (running packs together) are safe and reduce withdrawal symptoms.

Tailored regimens: running packs together

The traditional 21/7 regimen was designed to mimic a natural menstrual cycle, but there is no medical need for a monthly withdrawal bleed.

The FSRH supports flexible and extended regimens for all monophasic COCs, including Microgynon 30.

Continuous use involves running packs together indefinitely, taking a 4-day break only if breakthrough bleeding occurs for 3 or more consecutive days.

A 63/4 regimen means taking 63 active pills (3 packs) followed by a 4-day break.

A 21/4 regimen shortens the standard break from 7 to 4 days, reducing the risk of ovulation during the break.

These approaches can reduce headaches, mood changes, period pain, and other symptoms that arise during the hormone-free interval.

Side effects of Microgynon 30

Common side effects

Headache, breast tenderness, mood changes (including low mood and irritability), nausea, and breakthrough bleeding are the most commonly reported side effects.

Breakthrough bleeding is more likely during the first 2 to 3 cycles. Other common effects include bloating, mild weight fluctuation, and changes in libido.

These often improve with continued use.

Venous thromboembolism

The most clinically significant risk of combined oral contraceptives is venous thromboembolism (VTE).

For Microgynon 30, the estimated incidence is 5 to 7 per 10,000 users per year, compared with 2 per 10,000 non-users.

The risk is highest in the first year of use and after restarting following a break of 4 weeks or more.

Symptoms of DVT include sudden leg swelling, pain, and redness. Symptoms of PE include sudden breathlessness and chest pain. Call 999 immediately if these symptoms occur.

Arterial thromboembolism

Myocardial infarction and ischaemic stroke are rare but associated with COC use in the presence of additional risk factors: smoking over age 35, hypertension, migraine with aura, diabetes with vascular complications, and hyperlipidaemia.

The FSRH advises that COCs must not be prescribed to women with migraine with aura at any age.

Other important side effects

Blood pressure should be checked annually. Very rare liver tumours (hepatocellular adenoma) and slightly increased gallbladder disease risk have been reported.

A very small increase in breast cancer risk during use disappears within 10 years of stopping.

Long-term use is associated with a small increase in cervical cancer risk that declines after discontinuation.

When to seek urgent medical advice

Stop Microgynon 30 and call 999 if you develop sudden severe headache, visual disturbance, leg pain or swelling, chest pain, breathlessness, or stroke symptoms (facial drooping, arm weakness, speech difficulty).

Contact your GP or call NHS 111 for persistent mood changes, new migraines, or sustained blood pressure changes. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Microgynon 30 is contraindicated in women with current or past VTE or arterial thromboembolism, known thrombophilia, uncontrolled hypertension, migraine with aura, diabetes with vascular complications, severe hepatic disease or liver tumours, pancreatitis associated with hypertriglyceridaemia, known or suspected sex-steroid-dependent malignancies, undiagnosed vaginal bleeding, or hypersensitivity to any ingredient.

Risk assessment before prescribing

Blood pressure, BMI, smoking status, personal and family VTE history, cardiovascular history, migraine history, and current medications should be assessed before starting Microgynon 30 and reviewed annually. The UKMEC system guides suitability decisions.

Surgery and immobility

If major surgery with prolonged immobilisation is planned, your prescriber may advise stopping Microgynon 30 four to six weeks before the procedure and restarting when you are fully mobile.

During long-haul flights, staying hydrated, wearing compression stockings, and moving regularly help reduce VTE risk.

Drug interactions

Enzyme-inducing medicines (rifampicin, rifabutin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, topiramate at doses above 200 mg, certain antiretrovirals, St John's wort) reduce COC effectiveness by increasing hepatic metabolism.

Additional contraception or an alternative method is needed during and after use of these medicines.

Combined hormonal contraceptives may reduce lamotrigine levels; this interaction should be discussed with the prescriber if you take lamotrigine for epilepsy.

Pregnancy and breastfeeding

Microgynon 30 must not be taken during pregnancy. If pregnancy occurs while taking the pill, stop immediately.

There is no evidence of harm from accidental exposure in early pregnancy.

Combined pills are not recommended during breastfeeding in the first 6 weeks postpartum and are generally avoided until 6 months postpartum if fully breastfeeding.

A progestogen-only method is preferred.

How to get Microgynon 30 in the UK

Microgynon 30 is a prescription-only medicine available through the NHS.

You can obtain a prescription from your GP, a sexual health or family planning clinic, or an authorised online prescriber registered with the GPhC.

Contraception, including the pill, is free on the NHS throughout the United Kingdom.

If obtained via a standard NHS prescription outside a contraceptive clinic, the usual charge of 9.90 pounds applies in England; prescriptions are free in Scotland, Wales, and Northern Ireland.

Lifestyle advice while taking Microgynon 30

No specific dietary restrictions apply when taking Microgynon 30. If you smoke, stopping is strongly recommended, as smoking while taking a combined pill significantly raises cardiovascular risk.

Limit alcohol to 14 units per week, spread across 3 or more days. Stay physically active and maintain a healthy weight.

Attend cervical screening as invited by the NHS Cervical Screening Programme. Be breast-aware and report changes to your GP.

Sources

• Microgynon 30, Summary of Product Characteristics (EMC)
• Levonorgestrel with ethinylestradiol, British National Formulary (BNF)
• FSRH Clinical Guideline: Combined Hormonal Contraception
• Combined pill, NHS
• MHRA Yellow Card Scheme